3371 Stock Chart & Stats
€9.62
-€0.12(-1.47%)
At close: 4:00 PM EDT
€9.62
-€0.12(-1.47%)
Day’s Range― - ―
52-Week Range€5.26 - €18.40
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€105.56M
Enterprise Value€68.37M
Total Cash (Recent Filing)€117.94M
Total Debt (Recent Filing)€4.26M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Nov 10, 2026EPS Estimate
-1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.19
Shares Outstanding19,341,293
10 Day Avg. Volume0
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€32.57Price Target Upside238.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-4.84
Revenue Forecast (FY)€1.48M
Bulls Say, Bears Say
Bulls Say
CRB-913 Clinical DifferentiationCRB-913’s early obesity data indicate both meaningful efficacy and a potentially differentiated tolerability profile. If reproduced in later trials, this combination could support adoption, strengthen Corbus’s position in oral obesity treatment, and expand the company’s development platform.
CRB-701 Late-stage AdvancementFDA clearance to begin a registrational Phase 3 study materially advances CRB-701 toward a potential commercial product. Progress into a pivotal trial creates a clearer development pathway, increases the program’s strategic significance, and provides an important foundation for future partnering or regulatory value.
Liquidity And Low LeverageA reported liquidity runway into 2028 gives Corbus time to advance multiple clinical programs without immediate reliance on new financing. Combined with very low reported leverage, this provides greater flexibility to fund trials and reach development milestones before seeking additional capital.
Bears Say
Pre-revenue Business ModelWithout approved products or recurring commercial revenue, Corbus remains dependent on clinical success and external funding to support operations. This limits financial visibility, leaves no established sales base to absorb research spending, and makes future business value highly dependent on pipeline outcomes.
Widening Net LossesThe sharp expansion in net losses shows that advancing the pipeline is requiring substantially more spending while revenue remains absent. Persistent losses can erode equity, reduce financial flexibility, and increase the amount of capital Corbus may ultimately need to fund later-stage development.
Accelerating Cash BurnAccelerating operating and free-cash-flow deficits increase funding risk even with the currently reported liquidity runway. A higher burn rate can shorten the period available to reach clinical milestones, raise dependence on capital markets, and create dilution or financing pressure over time.
Corbus Pharmaceuticals News
3371 FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest stock price was €5.25 and its highest was €18.40 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Corbus Pharmaceuticals’s market cap is €105.56M.
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is Nov 10, 2026 which is in 36 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -€1.612 earnings per share for the quarter, missing the consensus estimate of -€1.121 by -€0.491.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -1.08.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 19,341,293 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -€1.612 in its last earnings report, missing expectations of -€1.121. Following the earnings report the stock price went up 1.65%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:3371
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corbus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€32.57 (238.52% Upside)
€32.57 (238.52% Upside)
Blogger Sentiment
Bullish
DE:3371 Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth €22.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
3371 Stock 12 Month Forecast
Average Price Target
€32.57
▲(238.52% Upside)